ENvue Medical Enters $50M Committed Equity Facility; Series H Amendment

What Happened

• On August 12, 2026, ENvue Medical, Inc. (FEED) entered into a Common Shares Purchase Agreement providing a committed equity facility under which the company may sell up to $50.0 million of common stock to an institutional investor at the company’s option. Sales require certain conditions (including an effective resale registration statement) and, upon Commencement, the company may direct purchases for up to 36 months (until the first day of the month following that 36‑month period).
• The company also entered a Second Amendment (same date) to its Series H Purchase Agreement to increase the Additional Investment Rights to a total stated value of $59,000,000 (representing 59,000 Series H preferred shares and a $53.1M subscription amount), subject to shareholder approval.

Key Details

• Facility size: up to $50.0 million of common shares available for sale to the investor.
• Pricing: each placement price will be 90% of the lowest volume‑weighted average price (VWAP) of FEED common stock over the three trading days immediately preceding a purchase notice.
• Required use of proceeds: 40% of net proceeds from any sales must be used to redeem outstanding Series X Preferred Stock until none remain; remaining net proceeds for working capital and general corporate purposes.
• Series H amendment: increases Additional Investment Rights to $59M stated value; subject to shareholder approval, the investor agreed to commit at least $10.0M within 12 months after approval with a $833,333.33 monthly minimum (reducible dollar‑for‑dollar by certain fundraising events).

Why It Matters

• This facility gives ENvue a ready source of capital, which can extend cash runway without negotiating new loans, but it can dilute existing shareholders because new common shares may be issued.
• The 90%-of-lowest‑VWAP pricing represents a potential discount to market when shares are sold, increasing dilution risk per dollar raised.
• The required 40% redemption of Series X preferred stock reduces preferred‑stock obligations but also directs a significant portion of proceeds away from general operations.
• The expanded Series H investment rights (subject to shareholder approval) create another potential source of capital (and future dilution) tied to the investor’s commitments.